{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:27:44Z","timestamp":1794551264126,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10787-026-02413-0","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:22:06Z","timestamp":1790331726000},"page":"6991-7007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rewiring the psoriasis\u2013metabolism axis: therapeutic potential of saroglitazar beyond PPAR modulation"],"prefix":"10.1007","volume":"34","author":[{"given":"Kanika","family":"Vashisht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendra Singh","family":"Ashawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-2774","authenticated-orcid":false,"given":"Shiv Kumar","family":"Kushawaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"1","key":"2413_CR1","first-page":"7","volume":"3","author":"A Aggarwal","year":"2014","unstructured":"Aggarwal A (2014) Saroglitazar: India\u2019s answer to diabetic Dyslipidemia. Int J Pharmacol Clin Sci 3(1):7","journal-title":"Int J Pharmacol Clin Sci"},{"issue":"2","key":"2413_CR2","doi-asserted-by":"publisher","first-page":"e70028","DOI":"10.1002\/der2.70028","volume":"6","author":"MS Al-Dhubaibi","year":"2025","unstructured":"Al-Dhubaibi MS et al (2025) The role of keratinocytes in skin health and disease. Dermatological Rev 6(2):e70028. https:\/\/doi.org\/10.1002\/der2.70028","journal-title":"Dermatological Reviews"},{"key":"2413_CR3","doi-asserted-by":"publisher","first-page":"113407","DOI":"10.1016\/j.intimp.2024.113407","volume":"143","author":"A Alharbi","year":"2024","unstructured":"Alharbi A et al (2024) Saroglitazar ameliorates 5-Fluorouracil-induced hepatorenal damage in rats. Int Immunopharmacol 143:113407. https:\/\/doi.org\/10.1016\/j.intimp.2024.113407","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"2413_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/cells15070594","volume":"15","author":"K Andrzejczak","year":"2026","unstructured":"Andrzejczak K et al (2026) Gut dysbiosis and the molecular landscape of the gut\u2013skin axis: comparative insights and therapeutic implications for atopic dermatitis and psoriasis. Cells 15(7):594. https:\/\/doi.org\/10.3390\/cells15070594","journal-title":"Cells"},{"issue":"12","key":"2413_CR5","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1182\/blood-2004-12-4709","volume":"106","author":"S Appel","year":"2005","unstructured":"Appel S et al (2005) PPAR-\u03b3 agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-\u03baB pathways. Blood 106(12):3888\u20133894. https:\/\/doi.org\/10.1182\/blood-2004-12-4709","journal-title":"Blood"},{"issue":"14","key":"2413_CR6","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.3390\/ijms23147499","volume":"23","author":"G Barros","year":"2022","unstructured":"Barros G, Duran P, Vera I, Berm\u00fadez V (2022) Exploring the links between obesity and psoriasis: a comprehensive review. Int J Mol Sci 23(14):7499. https:\/\/doi.org\/10.3390\/ijms23147499","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2413_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1089\/vim.2010.0016","volume":"23","author":"J Bassaganya-Riera","year":"2010","unstructured":"Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R (2010) PPAR-\u03b3 activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 23(4):343\u2013352. https:\/\/doi.org\/10.1089\/vim.2010.0016","journal-title":"Viral Immunol"},{"issue":"1","key":"2413_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/cells9010037","volume":"9","author":"J Boeckmans","year":"2019","unstructured":"Boeckmans J et al (2019) Anti-NASH drug development hitches a lift on PPAR agonism. Cells 9(1):37. https:\/\/doi.org\/10.3390\/cells9010037","journal-title":"Cells"},{"issue":"6","key":"2413_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/biom14060728","volume":"14","author":"S Briganti","year":"2024","unstructured":"Briganti S et al (2024) New insights into the role of PPAR\u03b3 in skin physiopathology. Biomolecules 14(6):728. https:\/\/doi.org\/10.3390\/biom14060728","journal-title":"Biomolecules"},{"issue":"7","key":"2413_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/09546634.2019.1610552","volume":"31","author":"G Chang","year":"2020","unstructured":"Chang G, Wang J, Song J, Zhang Z, Zhang L (2020) Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatological Treat 31(7):680\u2013686. https:\/\/doi.org\/10.1080\/09546634.2019.1610552","journal-title":"J Dermatological Treat"},{"issue":"1\u20132","key":"2413_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1515\/jbcpp-2023-0254","volume":"35","author":"O Chatterjee","year":"2024","unstructured":"Chatterjee O, Sur D (2024) Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in an imiquimod-induced psoriasis model in rat. J Basic Clin Physiol Pharmacol 35(1\u20132):45\u201352. https:\/\/doi.org\/10.1515\/jbcpp-2023-0254","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"32","key":"2413_CR12","doi-asserted-by":"publisher","first-page":"e21549","DOI":"10.1097\/MD.0000000000021549","volume":"99","author":"P Chen","year":"2020","unstructured":"Chen P et al (2020) The efficacy and safety of pioglitazone in psoriasis vulgaris: a meta-analysis of randomized controlled trials. Medicine 99(32):e21549. https:\/\/doi.org\/10.1097\/MD.0000000000021549","journal-title":"Medicine"},{"issue":"4","key":"2413_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.4103\/ijd.ijd_569_22","volume":"67","author":"S Chhabra","year":"2022","unstructured":"Chhabra S et al (2022) Recent update on immunopathogenesis of psoriasis. Indian J Dermatology 67(4):360\u2013373. https:\/\/doi.org\/10.4103\/ijd.ijd_569_22","journal-title":"Indian J Dermatology"},{"issue":"5","key":"2413_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s13205-023-03533-y","volume":"13","author":"S Choudhary","year":"2023","unstructured":"Choudhary S et al (2023) Exploring the molecular underpinning of psoriasis and its associated comorbidities through network approach: cross talks of genes and pathways. 3 Biotech 13(5):130. https:\/\/doi.org\/10.1007\/s13205-023-03533-y","journal-title":"3 Biotech"},{"key":"2413_CR15","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3389\/fphar.2018.01382","volume":"9","author":"M \u00d0ani\u0107","year":"2018","unstructured":"\u00d0ani\u0107 M et al (2018) Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol 9:1382. https:\/\/doi.org\/10.3389\/fphar.2018.01382","journal-title":"Front Pharmacol"},{"issue":"1","key":"2413_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/10408444.2017.1351420","volume":"48","author":"MA Davidson","year":"2018","unstructured":"Davidson MA, Mattison DR, Azoulay L, Krewski D (2018) Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol 48(1):52\u2013108. https:\/\/doi.org\/10.1080\/10408444.2017.1351420","journal-title":"Crit Rev Toxicol"},{"issue":"3","key":"2413_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12016-016-8535-x","volume":"50","author":"Y Deng","year":"2016","unstructured":"Deng Y, Chang C, Lu Q (2016) The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol 50(3):377\u2013389. https:\/\/doi.org\/10.1007\/s12016-016-8535-x","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2413_CR17","doi-asserted-by":"publisher","first-page":"e70020","DOI":"10.1002\/mef2.70020","volume":"4","author":"W Deng","year":"2025","unstructured":"Deng W et al (2025) Critical role of skin in pathogenesis: bidirectional crosstalk between skin and multiple organs. MedComm\u2013Future Med 4(2):e70020","journal-title":"MedComm\u2013Future Med"},{"issue":"4","key":"2413_CR19","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/ijms23042104","volume":"23","author":"I Drenjan\u010devi\u0107","year":"2022","unstructured":"Drenjan\u010devi\u0107 I, Pitha J (2022) Omega-3 polyunsaturated fatty acids\u2014vascular and cardiac effects on the cellular and molecular level (narrative review). Int J Mol Sci 23(4):2104. https:\/\/doi.org\/10.3390\/ijms23042104","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2413_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbrc.2018.11.083","volume":"508","author":"SN Dumas","year":"2019","unstructured":"Dumas SN et al (2019) Interleukin-6 derived from cutaneous deficiency of stearoyl-CoA desaturase-1 may mediate metabolic organ crosstalk among skin, adipose tissue and liver. Biochem Biophys Res Commun 508(1):87\u201391. https:\/\/doi.org\/10.1016\/j.bbrc.2018.11.083","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2413_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40261-022-01219-6","volume":"42","author":"DR Durga","year":"2022","unstructured":"Durga DR, Mounika N, Mudimala P, Adela R (2022) Efficacy and safety of saroglitazar in patients with cardiometabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig 42(12):1049\u20131064. https:\/\/doi.org\/10.1007\/s40261-022-01219-6","journal-title":"Clin Drug Investig"},{"issue":"2","key":"2413_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/dermatopathology12020017","volume":"12","author":"A Fadel","year":"2025","unstructured":"Fadel A et al (2025) Erythrodermic psoriasis in the context of emerging triggers: insights into dupilumab-associated and COVID-19-induced psoriatic disease. Dermatopathology 12(2):17. https:\/\/doi.org\/10.3390\/dermatopathology12020017","journal-title":"Dermatopathology"},{"issue":"6","key":"2413_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.5935\/abc.20190224","volume":"113","author":"F Ferrari","year":"2019","unstructured":"Ferrari F, Bock PM, Motta MT, Helal L (2019) Biochemical and molecular mechanisms of glucose uptake stimulated by physical exercise in insulin resistance state: role of inflammation. Arquivos brasileiros de cardiologia 113(6):1139\u20131148. https:\/\/doi.org\/10.5935\/abc.20190224","journal-title":"Arquivos brasileiros de cardiologia"},{"issue":"14","key":"2413_CR24","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3390\/nu15143123","volume":"15","author":"T Gao","year":"2023","unstructured":"Gao T, Wang X, Li Y, Ren F (2023) The role of probiotics in skin health and related gut\u2013skin axis: A review. Nutrients 15(14):3123. https:\/\/doi.org\/10.3390\/nu15143123","journal-title":"Nutrients"},{"issue":"4","key":"2413_CR25","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","volume":"74","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S et al (2021) Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double\u2010blind phase 2 trial. Hepatology 74(4):1809\u20131824. https:\/\/doi.org\/10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"2413_CR26","volume-title":"Principles of Free Radical Biomedicine","author":"N Grandvaux","year":"2012","unstructured":"Grandvaux N (2012) NF-B transcription factor: mechanism of redox regulation. Principles of free radical biomedicine. Nova Science, Volume II"},{"issue":"12","key":"2413_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2165\/00128071-200304120-00003","volume":"4","author":"MA Gupta","year":"2003","unstructured":"Gupta MA, Gupta AK (2003) Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 4(12):833\u2013842. https:\/\/doi.org\/10.2165\/00128071-200304120-00003","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2413_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.33549\/physiolres.930744","volume":"55","author":"M Haluzik","year":"2006","unstructured":"Haluzik M, Haluzik M (2006) PPAR-alpha and insulin sensitivity. Physiol Res 55(2):115. https:\/\/doi.org\/10.33549\/physiolres.930744","journal-title":"Physiol Res"},{"issue":"10","key":"2413_CR29","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1021\/cr2001355","volume":"111","author":"GS Harmon","year":"2011","unstructured":"Harmon GS, Lam MT, Glass CK (2011a) PPARs and lipid ligands in inflammation and metabolism. Chem Rev 111(10):6321\u20136340. https:\/\/doi.org\/10.1021\/cr2001355","journal-title":"Chem Rev"},{"issue":"10","key":"2413_CR30","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1021\/cr2001355","volume":"111","author":"GS Harmon","year":"2011","unstructured":"Harmon GS, Lam MT, Glass CK (2011b) PPARs and lipid ligands in inflammation and metabolism. Chem Rev 111(10):6321. https:\/\/doi.org\/10.1021\/cr2001355","journal-title":"Chem Rev"},{"issue":"3","key":"2413_CR31","doi-asserted-by":"publisher","first-page":"e00136","DOI":"10.1002\/prp2.136","volume":"3","author":"MR Jain","year":"2015","unstructured":"Jain MR et al (2015) Saroglitazar, a novel PPAR\u03b1\/\u03b3 agonist with predominant PPAR\u03b1 activity, shows lipid-lowering and insulin\u2010sensitizing effects in preclinical models. Pharmacol Res Perspect 3(3):e00136. https:\/\/doi.org\/10.1002\/prp2.136","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"2413_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40261-013-0128-3","volume":"33","author":"RH Jani","year":"2013","unstructured":"Jani RH et al (2013) Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPAR\u03b1 agonist with moderate PPAR\u03b3 agonist activity in healthy human subjects. Clin Drug Investig 33(11):809\u2013816. https:\/\/doi.org\/10.1007\/s40261-013-0128-3","journal-title":"Clin Drug Investig"},{"key":"2413_CR33","doi-asserted-by":"publisher","first-page":"106577","DOI":"10.1016\/j.vph.2019.106577","volume":"121","author":"F Kamau","year":"2019","unstructured":"Kamau F et al (2019) Antiretroviral drug-induced endothelial dysfunction is improved by dual PPAR\u03b1\/\u03b3 stimulation in obesity. Vascul Pharmacol 121:106577. https:\/\/doi.org\/10.1016\/j.vph.2019.106577","journal-title":"Vascul Pharmacol"},{"issue":"4","key":"2413_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s42000-024-00588-1","volume":"23","author":"A Katsarou","year":"2024","unstructured":"Katsarou A et al (2024) Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease. Hormones 23(4):621\u2013636. https:\/\/doi.org\/10.1007\/s42000-024-00588-1","journal-title":"Hormones"},{"issue":"3","key":"2413_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1523-1747.2000.00073.x","volume":"115","author":"LG K\u00f6m\u00fcves","year":"2000","unstructured":"K\u00f6m\u00fcves LG et al (2000) Stimulation of PPAR\u03b1 promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatology 115(3):353\u2013360. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00073.x","journal-title":"J Invest Dermatology"},{"issue":"1","key":"2413_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-020-01073-w","volume":"19","author":"M Krishnappa","year":"2020","unstructured":"Krishnappa M et al (2020) Effect of saroglitazar 2\u00a0mg and 4\u00a0mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc Diabetol 19(1):93. https:\/\/doi.org\/10.1186\/s12933-020-01073-w","journal-title":"Cardiovasc Diabetol"},{"key":"2413_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2018.01.002","volume":"822","author":"D Kumar","year":"2018","unstructured":"Kumar D et al (2018) Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue. Eur J Pharmacol 822:32\u201342. https:\/\/doi.org\/10.1016\/j.ejphar.2018.01.002","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2413_CR38","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","volume":"10","author":"DP Kumar","year":"2020","unstructured":"Kumar DP et al (2020) The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet-induced animal model of nonalcoholic fatty liver disease. Sci Rep 10(1):9330. https:\/\/doi.org\/10.1038\/s41598-020-66458-z","journal-title":"Sci Rep"},{"key":"2413_CR79","doi-asserted-by":"publisher","unstructured":"Kumari D et al (2023) Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL\/6J mice. Heliyon 9(11):22051. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22051","DOI":"10.1016\/j.heliyon.2023.e22051"},{"issue":"7","key":"2413_CR39","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1007\/s10787-025-01805-y","volume":"33","author":"SK Kushawaha","year":"2025","unstructured":"Kushawaha SK et al (2025) Repurposing Saroglitazar for neurodegenerative disorders: insight into molecular signalling pathways and neuroprotective modulations. Inflammopharmacology 33(7):3805\u20133822. https:\/\/doi.org\/10.1007\/s10787-025-01805-y","journal-title":"Inflammopharmacology"},{"key":"2413_CR80","doi-asserted-by":"publisher","unstructured":"Kung J, Henry RR (2012) Thiazolidinedione safety. Expert Opin Drug Saf 11(4):565-579. https:\/\/doi.org\/10.1517\/14740338.2012.691963","DOI":"10.1517\/14740338.2012.691963"},{"issue":"1","key":"2413_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/metabo13010096","volume":"13","author":"LF Laurindo","year":"2023","unstructured":"Laurindo LF et al (2023) Phytochemicals and regulation of NF-kB in inflammatory bowel diseases: an overview of in vitro and in vivo effects. Metabolites 13(1):96. https:\/\/doi.org\/10.3390\/metabo13010096","journal-title":"Metabolites"},{"issue":"7","key":"2413_CR41","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s11010-022-04417-0","volume":"477","author":"X Lin","year":"2022","unstructured":"Lin X, Meng X, Song Z, Lin J (2022a) Peroxisome proliferator-activated receptor \u03b3 and psoriasis, molecular and cellular biochemistry. Mol Cell Biochem 477(7):1905\u20131920. https:\/\/doi.org\/10.1007\/s11010-022-04417-0","journal-title":"Mol Cell Biochem"},{"key":"2413_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcdb.2021.06.018","volume":"128","author":"Y Lin","year":"2022","unstructured":"Lin Y, Zhang W, Li B, Wang G (2022b) Keratin 17 in psoriasis: current understanding and future perspectives. Semin Cell Dev Biol 128:112\u2013119. https:\/\/doi.org\/10.1016\/j.semcdb.2021.06.018","journal-title":"Semin Cell Dev Biol"},{"key":"2413_CR43","doi-asserted-by":"publisher","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T et al (2020) The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol 11:594735. https:\/\/doi.org\/10.3389\/fimmu.2020.594735","journal-title":"Front Immunol"},{"issue":"12","key":"2413_CR44","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.3390\/ijms23126456","volume":"23","author":"LT Majnari\u0107","year":"2022","unstructured":"Majnari\u0107 LT, Bosni\u0107 Z, \u0160tefani\u0107 M, Wittlinger T (2022) Cross-talk between the cytokine IL-37 and thyroid hormones in modulating chronic inflammation associated with target organ damage in age-related metabolic and vascular conditions. Int J Mol Sci 23(12):6456. https:\/\/doi.org\/10.3390\/ijms23126456","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2413_CR45","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3390\/v14091980","volume":"14","author":"S Mediouni","year":"2022","unstructured":"Mediouni S, Lyu S, Schader SM, Valente ST (2022) Forging a functional cure for HIV: transcription regulators and inhibitors. Viruses 14(9):1980. https:\/\/doi.org\/10.3390\/v14091980","journal-title":"Viruses"},{"key":"2413_CR46","unstructured":"Moradi M (2017) Health-related quality of life and disease burden of psoriasis in Iran. Dissertation, Budapesti Corvinus Egyetem"},{"issue":"5","key":"2413_CR47","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1046\/j.0022-202x.2001.01323.x","volume":"116","author":"KP O\u2019Brien","year":"2001","unstructured":"O\u2019Brien KP et al (2001) The HCR gene on 6p21 is unlikely to be a psoriasis susceptibility gene. J Invest Dermatology 116(5):750\u2013754","journal-title":"J Invest Dermatology"},{"issue":"1","key":"2413_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4933-4-1","volume":"4","author":"S Omoigui","year":"2007","unstructured":"Omoigui S (2007) The Interleukin-6 inflammation pathway from cholesterol to aging\u2013Role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing 4(1):1. https:\/\/doi.org\/10.1186\/1742-4933-4-1","journal-title":"Immun Ageing"},{"issue":"1","key":"2413_CR49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1932296813518680","volume":"8","author":"V Pai","year":"2014","unstructured":"Pai V et al (2014) A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4\u00a0mg compared to pioglitazone 45\u00a0mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol 8(1):132\u2013141","journal-title":"J Diabetes Sci Technol"},{"key":"2413_CR81","doi-asserted-by":"publisher","unstructured":"Papa V et al (2024) Skin disorders and osteoporosis: unraveling the interplay between vitamin D, Microbiota, and epigenetics within the skin\u2013bone axis. Int J Mol Sci 26(1):179. https:\/\/doi.org\/10.3390\/ijms26010179","DOI":"10.3390\/ijms26010179"},{"issue":"1","key":"2413_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm2083","volume":"8","author":"ND Perkins","year":"2007","unstructured":"Perkins ND (2007) Integrating cell-signalling pathways with NF-\u03baB and IKK function. Nat Rev Mol Cell Biol 8(1):49\u201362. https:\/\/doi.org\/10.1038\/nrm2083","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2413_CR51","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.repbio.2020.05.004","volume":"20","author":"YD Prabhu","year":"2020","unstructured":"Prabhu YD, Gopalakrishnan AV (2020) \u03b3-Linolenic acid ameliorates DHEA-induced pro-inflammatory response in polycystic ovary syndrome via PPAR-\u03b3 signaling in rats. Reprod Biol 20(3):348\u2013356. https:\/\/doi.org\/10.1016\/j.repbio.2020.05.004","journal-title":"Reprod Biol"},{"key":"2413_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fcell.2019.00317","volume":"7","author":"D Queen","year":"2019","unstructured":"Queen D, Ediriweera C, Liu L (2019) Function and regulation of IL-36 signaling in inflammatory diseases and cancer development. Front cell Dev biology 7:317","journal-title":"Front cell Dev biology"},{"issue":"3","key":"2413_CR53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/1568026611313030012","volume":"13","author":"O Radresa","year":"2013","unstructured":"Radresa O, Par\u00e9 M,S, Albert J (2013) Multiple roles of transient receptor potential (TRP) channels in inflammatory conditions and current status of drug development. Curr Top Med Chem 13(3):367\u2013385","journal-title":"Curr Top Med Chem"},{"key":"2413_CR54","doi-asserted-by":"publisher","first-page":"873699","DOI":"10.3389\/fendo.2022.873699","volume":"13","author":"Y Ren","year":"2022","unstructured":"Ren Y et al (2022) Adipokines, hepatokines and myokines: focus on their role and molecular mechanisms in adipose tissue inflammation. Front Endocrinol 13:873699","journal-title":"Front Endocrinol"},{"issue":"10","key":"2413_CR55","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.tem.2020.03.004","volume":"31","author":"M Rocha","year":"2020","unstructured":"Rocha M et al (2020) Mitochondria and T2D: role of autophagy, ER stress, and inflammasome. Trends Endocrinol Metabolism 31(10):725\u2013741","journal-title":"Trends Endocrinol Metabolism"},{"issue":"20","key":"2413_CR56","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3390\/diagnostics13203167","volume":"13","author":"N Saito-Sasaki","year":"2023","unstructured":"Saito-Sasaki N, Sawada Y (2023) S100 proteins in the pathogenesis of psoriasis and atopic dermatitis. Diagnostics 13(20):3167","journal-title":"Diagnostics"},{"key":"2413_CR57","doi-asserted-by":"publisher","first-page":"803218","DOI":"10.3389\/fbioe.2022.803218","volume":"10","author":"R Sarama","year":"2022","unstructured":"Sarama R et al (2022) In vitro disease models for understanding psoriasis and atopic dermatitis. Front Bioeng Biotechnol 10:803218. https:\/\/doi.org\/10.3389\/fbioe.2022.803218","journal-title":"Front Bioeng Biotechnol"},{"key":"2413_CR58","unstructured":"Schwab M (2008) PPARgamma as molecular target of epithelial functions in the gastrointestinal tract. Universit\u00e4tsbibliothek Johann Christian Senckenberg"},{"key":"2413_CR78","doi-asserted-by":"publisher","unstructured":"Secchiero P et al (2024) Metabolic syndrome and psoriasis: pivotal roles of chronic inflammation and gut microbiota. Int J Mol Sci 25(15):8098. https:\/\/doi.org\/10.3390\/ijms25158098","DOI":"10.3390\/ijms25158098"},{"issue":"1","key":"2413_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12895-016-0049-y","volume":"16","author":"S Singh","year":"2016","unstructured":"Singh S, Bhansali A (2016) Randomized placebo-controlled study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol 16(1):12. https:\/\/doi.org\/10.1186\/s12895-016-0049-y","journal-title":"BMC Dermatol"},{"issue":"6","key":"2413_CR59","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ajpath.2026.03.003","volume":"196","author":"H Singh","year":"2026","unstructured":"Singh H, Taliyan R (2026) Epigenetic and transcriptional regulatory networks underlying psoriasis pathogenesis. Am J Pathol 196(6):1245\u20131258. https:\/\/doi.org\/10.1016\/j.ajpath.2026.03.003","journal-title":"Am J Pathol"},{"issue":"4","key":"2413_CR61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s40496-022-00320-1","volume":"9","author":"S Singh","year":"2022","unstructured":"Singh S et al (2022) Role of pro-inflammatory and anti-inflammatory cytokines in the pathophysiology of psoriasis. Curr Oral Health Rep 9(4):132\u2013145","journal-title":"Curr Oral Health Rep"},{"issue":"8","key":"2413_CR62","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.immuni.2023.06.021","volume":"56","author":"P Sivasami","year":"2023","unstructured":"Sivasami P et al (2023) Obesity-induced dysregulation of skin-resident PPAR\u03b3\u2009+\u2009Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity 56(8):1844\u20131861. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.021","journal-title":"Immunity"},{"issue":"17","key":"2413_CR63","doi-asserted-by":"publisher","first-page":"9708","DOI":"10.3390\/ijms23179708","volume":"23","author":"VV Sobolev","year":"2022","unstructured":"Sobolev VV et al (2022) The role of transcription factor PPAR-\u03b3 in the pathogenesis of psoriasis, skin cells, and immune cells. Int J Mol Sci 23(17):9708. https:\/\/doi.org\/10.3390\/ijms23179708","journal-title":"Int J Mol Sci"},{"key":"2413_CR64","doi-asserted-by":"publisher","unstructured":"Sosale A, Saboo B, Sosale B (2015) Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence. Diabetes Metabolic Syndrome Obes Targets Therapy 8:189\u2013196. https:\/\/doi.org\/10.2147\/DMSO.S49592","DOI":"10.2147\/DMSO.S49592"},{"issue":"48","key":"2413_CR65","doi-asserted-by":"publisher","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","volume":"20","author":"S Stojsavljevi\u0107","year":"2014","unstructured":"Stojsavljevi\u0107 S et al (2014) Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterology: WJG 20(48):18070. https:\/\/doi.org\/10.3748\/wjg.v20.i48.18070","journal-title":"World J Gastroenterology: WJG"},{"issue":"36","key":"2413_CR67","doi-asserted-by":"publisher","first-page":"eaau9657","DOI":"10.1126\/sciimmunol.aau9657","volume":"4","author":"Y Su","year":"2019","unstructured":"Su Y (2019) Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol 4(36):eaau9657","journal-title":"Sci Immunol"},{"key":"2413_CR66","doi-asserted-by":"publisher","first-page":"1279846","DOI":"10.3389\/fimmu.2023.1279846","volume":"14","author":"R Su","year":"2023","unstructured":"Su R et al (2023) Metabolic influences on T cell in psoriasis: a literature review. Front Immunol 14:1279846. https:\/\/doi.org\/10.3389\/fimmu.2023.1279846","journal-title":"Front Immunol"},{"key":"2413_CR68","unstructured":"Suttle MM (2019) Immunoregulatory mast cells in psoriasis: the role of the cytokines IL-33 and IL-6, IL-6 receptor, chymase, and regulatory T cells in experimentally induced psoriasis. Dissertation, University of Eastern Finland Kuopio"},{"issue":"11","key":"2413_CR69","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/dom.13826","volume":"21","author":"CJ Tack","year":"2019","unstructured":"Tack CJ et al (2019) Long-term efficacy and safety of combined insulin and glucagon\u2010like peptide\u20101 therapy: Evidence from the LEADER trial. Diabetes Obes Metabolism 21(11):2450\u20132458. https:\/\/doi.org\/10.1111\/dom.13826","journal-title":"Diabetes Obes Metabolism"},{"issue":"4","key":"2413_CR70","first-page":"319","volume":"12","author":"M Traub","year":"2007","unstructured":"Traub M, Marshall K (2007) Psoriasis\u2013pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev 12(4):319\u2013330","journal-title":"Altern Med Rev"},{"issue":"7","key":"2413_CR71","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3390\/medicina61071296","volume":"61","author":"OG Vaduva","year":"2025","unstructured":"Vaduva OG et al (2025) Dietary principles, interventions and oxidative stress in psoriasis management: current and future perspectives. Medicina 61(7):1296. https:\/\/doi.org\/10.3390\/medicina61071296","journal-title":"Medicina"},{"issue":"1","key":"2413_CR72","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cpt.3450","volume":"117","author":"R Vuppalanchi","year":"2025","unstructured":"Vuppalanchi R et al (2025) Pharmacokinetic, safety, and pharmacodynamic profiles of saroglitazar magnesium in cholestatic cirrhosis with hepatic impairment and participants with renal impairment. Clin Pharmacol Ther 117(1):240\u2013249","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2413_CR73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13024-025-00857-6","volume":"20","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang L, Qin C (2025) Alzheimer\u2019s disease pathogenesis: standing at the crossroads of lipid metabolism and immune response. Mol Neurodegeneration 20(1):67. https:\/\/doi.org\/10.1186\/s13024-025-00857-6","journal-title":"Mol Neurodegeneration"},{"issue":"3","key":"2413_CR74","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/metabo12030238","volume":"12","author":"RD Welch","year":"2022","unstructured":"Welch RD et al (2022) Emerging role of nuclear receptors for the treatment of NAFLD and NASH. Metabolites 12(3):238. https:\/\/doi.org\/10.3390\/metabo12030238","journal-title":"Metabolites"},{"key":"2413_CR75","doi-asserted-by":"publisher","first-page":"1574385","DOI":"10.3389\/fphar.2025.1574385","volume":"16","author":"X Zeng","year":"2025","unstructured":"Zeng X et al (2025) Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective. Front Pharmacol 16:1574385. https:\/\/doi.org\/10.3389\/fphar.2025.1574385","journal-title":"Front Pharmacol"},{"issue":"7","key":"2413_CR76","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/medicina61071157","volume":"61","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Lin J, Han X, Chen X (2025) Saroglitazar ameliorates pulmonary fibrosis progression in mice by suppressing NF-\u03baB activation and attenuating macrophage M1 polarization. Medicina 61(7):1157. https:\/\/doi.org\/10.3390\/medicina61071157","journal-title":"Medicina"},{"issue":"2","key":"2413_CR77","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/ph18020147","volume":"18","author":"JM Zimodro","year":"2025","unstructured":"Zimodro JM, Rizzo M, Gouni-Berthold I (2025) Current and emerging treatment options for hypertriglyceridemia: state-of-the-art review. Pharmaceuticals 18(2):147. https:\/\/doi.org\/10.3390\/ph18020147","journal-title":"Pharmaceuticals"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02413-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02413-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02413-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:44:43Z","timestamp":1794548683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02413-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2413"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02413-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"7 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}